Skin rashes and immune-associated pneumonitis caused by nivolumab combined with tegafur-gimeracil-oteracil potassium
10.3760/cma.j.cn114015-20220211-00112
- VernacularTitle:纳武利尤单抗与替吉奥联用致皮疹和免疫相关性肺炎
- Author:
Pengpeng SUN
1
;
Hui ZHANG
1
;
Yumin JIANG
1
;
Jingdong WANG
1
;
Meng ZHANG
1
Author Information
1. 青岛大学附属青岛市中心医院重症医学科，青岛 266042
- Publication Type:Journal Article
- Keywords:
Nivolumab;
Tegafur;
Drug eruptions;
Lung injury
- From:
Adverse Drug Reactions Journal
2022;24(9):497-499
- CountryChina
- Language:Chinese
-
Abstract:
A 69-year-old male patient was treated with nivolumab combined with tegafur-gimeraciloteracil potassium due to gastric adenocarcinoma with liver, pancreas, and abdominal lymph node metastasis after completing 4 cycles of chemotherapy with oxaliplatin and raltitrexed. Ten days later, the patient developed severe rashes all over the body, which was considered to be adverse skin reactions caused by nivolumab and tegafur-gimeracil-oteracil potassium. Then the 2 drugs were stopped and treatments with methylprednisolone and antiallergic drugs were given. The rashes were gradually improved, the dose of glucocorticoid was reduced gradually, and it was stopped at last. However, on the day of glucocorticoid withdrawal, the patient developed fever, chills, and severe respiratory failure. In combination with clinical treatment, laboratory test results, and imaging changes in the patient, it was considered to be immune-related pneumonitis caused by nivolumab. Methylprednisolone, anti-infection, and high-flow nasal cannula oxygen therapy were given. Four days later, the asthma symptoms in the patient were obviously improved, and 28 days later, the pulmonary CT showed the pneumonitis was markedly improved than before.
